Spektar vrednosti specifičnog antigena prostate kod lokalizovanog karcinoma prostate
Sažetak
Koncentracija specifičnog antigena prostate (engl. Prostate Specific Antigen, PSA) u serumu kod lokalizovanog karcinoma prostate (CaP) zavisi od faktora vezanih za tumor, prostatu i pacijenta. Tumorski faktori su zapremina, lokalizacija i brzina rasta tumora. Faktori vezani za prostatu su zapremina prostate, aktivnost dihidrotestosterona (DHT) u prostati i jačina sinteze PSA. Faktori vezani za pacijenta su androgeni status i ukupna zapremina krvi.
U ovom radu je predstavljena osnovna fiziologija PSA, kao i kratka istorija njegove kliničke primene, sa svim njenim ograničenjima. Osim toga, nabrojani su i analizirani svi poznati faktori koji su uzrok širokog spektra vrednosti PSA kod lokalizovanog CaP. Prikazani su i rezultati teorijskog matematičkog modela, pomoću koga delimično mogu da se objasne veze nabrojanih faktora i nivoa PSA u serumu.
Reference
Schieferstein G: Prostate-specific antigen (PSA) in human seminal plasma. Arch Androl 1999;42(3):193.
Lilja H: Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur Urol 2001;39(suppl 4):47-48.
Lilja H: Free and total PSA: background information and rationale for use. Recent advances in prostate cancer and BPH, Perthenon Publishing Group, UK, 1997;195-197.
Newling DWW: The use of markers in the diagnosis and monitoring of prostate cancer. Forum 5.3 (suppl.4) 1995.
Graves HC, Sensabaugh GF, Blake ET: Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med. 312:338-343, 1985.
Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM: Prostate antigen: a new potential marker for prostatic cancer.
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283-90.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol. 2010;28.
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-46.
Cohen RJ, Garett K, Golding JL, et al.: Epithelial differentiation of the lower urinary tract recognition of the minor prostatic glands. Hum Pathol. 2002;33(9):905-9.
Pejcić T, Hadzi-Djokić J, Marković B, Lalić N, Glisić B. What are the possible reasons for urethral PSA varieties after radical prostatectomy? Acta Chir Iugosl. 2010;57(2):31-5.
Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl. 2003;24(5):681-7.
Cohen RJ, McNeal JE, Redmond SL, Meehan K, Thomas R, Wilce M, Dawkins HJ: Luminal contents of benign and malignant prostatic glands: correspondence to altered secretory mechanisms. Hum Pathol 2001;32(2):242-3.
Vesey SG, Goble M, Ferro MA, Stower MJ, Hammonds JC, Smith PJB: Quantification of prostatic cancer metastatic disease using prostate specific antigen. Urology. 1990;35(6):483-486.
Erickson DR, Hlavinka TC, Rockwood AP, Metter JD, Novicki DE, Fried MG: Prostatic acid phosphatase, beta-glucuronidase and prostate specific antigen assays in fine needle aspirates from benign and malignant prostates. J Urol. 1991;146:1402-1406.
Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT: Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate. 2001;48(1):1-6.
Jung K, Brux B, Lein M, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Sinha P: Molecular forms of prostate specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin Chem. 46:1;47-54.
Ersev A, Ersev D, Turkery L, Ilker Y, Simsek F, Kullu S, Akdas A: The relation of prostatic acid phosphatase and prostate specific antigen with tumor grade in prostatic adenocarcinoma: an immunohistochemical study. EORTC Genitourinary Group Monograph. 1990;7:129-134.
Bostwick DG: Prostate specific antigen and pathology of the prostate. Eur urol. 1995;27(suppl 2):5.
Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, Bradley EL Jr: Tissue concentrations of prostate specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer. 1991;49(5):645-9.
Weir EG, Partin AW, Epstein JI: Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol. 2000;163(6):1739-42.
Manolović D, Pejcić T, Milović N. Prostatic specific antigen: role and significance in urologic practice. Srp Arh Celok Lek. 1994;122(5-6):171-3.
Billis A, Meirelles LR, Magna LA, Baracat J, Prando A, Ferreira U. Extent of prostatic atrophy in needle biopsies and serum PSA levels: is there an association? Urology. 2007;69(5):927-30.
Balk SP, Ko YJ, Bubley GJ: Biology of Prostate-Specific Antigen. J Clin Oncol. 2003; 21(2):383-391
Brawer MK. Laboratory studies for the detection of carcinoma of the prostate. Urol Clin North Am. 1990;17(4):759-68.
Richardson TD, Wojno KJ, Liang LW, Giacherio DA, England BG, Henricks WH, Schork A, Oesterling JE. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology. 1996;48(6A Suppl):40-4.
Stamey TA, Dietrick DD, Issa MM: large organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J Urol. 1993;149:510-515
Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT: prostate specific antigen and Gleason grade: an immunochistochemical study of prostate cancer. J Urol. 1994;151:1558-1564
Pejcic T, Hadzi-Djokic J, Markovic B, Maksimovic H, Acimovic M, Miljkovic S. Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. Acta Chir Iugosl. 2007;54(4):109-12.
Pejcić T, Hadzi-Djokić J, Topuzović C, Basić D, Marjanović A, Djurasic L. The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model. Acta Chir Iugosl. 2011;58(1):81-7.
McNeal JE: Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 1992;23(3):258-266.
Bostwick DG: progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol. 1996;30:145-152.
Pejčić T, Hadži-Đokić J, Bašić D. Prostata. Beograd, Elit medica. 2014;37..
Vesely S, Knutson T, Damber JE, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2003;37(4):322-8.
Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG; MTOPS RESEARCH Group. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422-6;
Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int J Impot Res. 2008;20(Suppl 3):S19-26.
T. Pejcic, J. Hadzi-Djokic, R. Radosavljevic, L. Hajdukovic, B. Milkovic. Can urinary PSA determination improve T-staging of prostate cancer? Urology. 2006;68:272.
Pejcic TP, Tulic CDz, Lalic NV, Glisic BD, Ignjatovic SD, Markovic BB, Hadzi-Djokic JB. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression? Can J Urol. 2013;20(2):6707-13.
Pejcic T, Hadzi-Djokic J, Acimovic M, Topuzovic C, Milkovic B, Janjic A. Urinary prostate specific antigen: is the clinical use likely? Acta Chir Iugosl. 2005;52(4):69-74.
Tomislav P. Pejčić. Prostata specifični antigen u urinu. Zadužbina Andrejević, Beograd, 2005.
Pejcić T, Hadzi-Djokić J, Marković B, Dragićević D, Glisić B, Lalić N, Aćimović M, Dzamić Z, Radosavljevic R. Urinary PSA level and relative tumor volume after prostate biopsy. Acta Chir Iugosl. 2009;56(2):17-21.
Yavuz BB, Ozkayar N, Halil M, Cankurtaran M, Ulger Z, Tezcan E, Gurlek A, Ariogul S. Free testosterone levels and implications on clinical outcomes in elderly men. Aging Clin Exp Res. 2008;20(3):201-6.
Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1041-7.
Gooren LJ, Saad F, Haide A, Yassin A. Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels. Andrologia. 2008;40(5):298-302.
Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, Porena M. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int. 2008;80(2):134-40.
Cameron, John R.; James G. Skofronick & Roderick M. Grant.Physics of the Body. Second Edition. Madison, WI: Medical Physics Publishing, 1999: 182.
Palken M, Cobb OE, Warren BH, Hoak DC. Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. J Urol. 1990;143(6):1155-62.
